Avian Mycoplasma Infections: Pathogenesis, Diagnosis, and Vaccination Strategies in Poultry
Introduction
Avian mycoplasmosis is a collective term for infectious diseases of poultry caused by several species of the genus Mycoplasma, principally Mycoplasma gallisepticum and Mycoplasma synoviae. These cell wall‑deficient bacteria are obligate parasites of the respiratory tract, synovial membranes, and reproductive organs of domestic fowl and turkeys. Infection results in chronic respiratory disease (CRD), infectious sinusitis, airsacculitis, synovitis, and egg production losses, leading to substantial economic impact worldwide (Diseases of Poultry, 13th ed.; Merck Veterinary Manual). This article reviews the etiology, pathogenesis, clinical presentation, diagnostic modalities, and vaccination strategies for controlling avian mycoplasma infections, with emphasis on molecular detection and the role of the poultry mycoplasma vaccine in integrated management programs.
Etiology and Epidemiology
The genus Mycoplasma comprises over 120 species, of which approximately 20 have been isolated from avian hosts (Diseases of Poultry). The most pathogenic species in commercial poultry are M. gallisepticum and M. synoviae. M. gallisepticum is the primary agent of CRD in chickens and infectious sinusitis in turkeys, while M. synoviae causes synovitis and subclinical respiratory disease that can exacerbate other infections (Merck Veterinary Manual). Other relevant species include Mycoplasma iowae (turkey embryo mortality and hatchery infections) and Mycoplasma meleagridis (turkey airsacculitis). The epidemiology of these infections is shaped by vertical transmission through the egg, horizontal spread via aerosol and fomites, and the carrier state in recovered birds. Multi‑age farms and live‑bird markets serve as reservoirs that perpetuate endemic cycles (Diseases of Poultry).
Pathogenesis
Mycoplasmas adhere to host epithelial cells via surface adhesins (e.g., GapA and CrmA in M. gallisepticum), followed by direct cytotoxicity and immune‑mediated damage. The absence of a cell wall renders these organisms resistant to β‑lactam antimicrobials and allows close membrane‑to‑membrane contact with host cells. Lipoproteins and cytadhesins trigger an intense inflammatory response characterized by infiltration of macrophages, lymphocytes, and heterophils into the tracheal mucosa, air sacs, and synovial membranes (Merck Veterinary Manual). In M. gallisepticum infection, the tracheal mucociliary apparatus is disrupted, predisposing birds to secondary bacterial infections such as Escherichia coli (avian colibacillosis). M. synoviae demonstrates tropism for joint synovia and tendon sheaths, producing fibrinopurulent exudates and cartilaginous erosion (Diseases of Poultry).
Clinical Signs and Pathology
Clinical manifestations vary with the species of mycoplasma, age of the host, concurrent infections, and environmental stressors. In M. gallisepticum infections, chickens exhibit rales, coughing, sneezing, conjunctivitis, nasal discharge, and reduced feed conversion. Turkeys may develop severe infraorbital sinus swelling and dyspnea. In laying hens, egg production may decline by 10–30%, and eggshell quality deteriorates (Merck Veterinary Manual). M. synoviae infection often presents as lameness, swollen joints (hock and wing joints), breast blisters, and walking on “stilts”. Subclinical respiratory forms are common and become apparent only under stress. Necropsy findings include catarrhal tracheitis, caseous airsacculitis (often with secondary E. coli), and fibrinous polyserositis. In M. synoviae, the synoviae contain turbid or purulent fluid, and the articular surfaces may show erosion (Diseases of Poultry).
Diagnosis
Accurate diagnosis is essential for control and relies on isolation, serological methods, and molecular techniques.
Isolation and Culture
Mycoplasmas are fastidious organisms requiring specialized growth media (e.g., Frey’s medium, Hayflick’s medium) supplemented with serum and nicotinamide adenine dinucleotide (NAD) for M. synoviae. Colony morphology on agar is characteristic: “fried‑egg” appearance for M. gallisepticum and smaller, smooth colonies for M. synoviae. Growth is slow (3–10 days) and can be inhibited by overgrowth of contaminants. Culture sensitivity is limited and is rarely used as a sole diagnostic method in commercial laboratories (Merck Veterinary Manual).
Serology
Serological screening is widely performed using commercial ELISA kits that detect antibodies against M. gallisepticum and M. synoviae. The serum plate agglutination (SPA) test is rapid and inexpensive but yields false positives due to cross‑reactions with other mycoplasma species and non‑specific agglutinins. The hemagglutination inhibition (HI) test is more specific and is the confirmatory assay for M. gallisepticum. Serology is useful for flock‑level surveillance but cannot distinguish natural infection from vaccine‑induced antibodies unless DIVA (differentiating infected from vaccinated animals) strategies are employed (Diseases of Poultry).
Molecular Diagnostics
Polymerase chain reaction (PCR) and real‑time PCR (qPCR) targeting species‑specific genes (e.g., mgc2 for M. gallisepticum, vlhA for M. synoviae) have become the gold standard for rapid, sensitive, and specific detection. Real‑time PCR allows quantification of bacterial load and can differentiate vaccine strains from field isolates using specific probes. Sequencing of the vlhA gene enables genotyping and epidemiological tracing. Pooled tracheal swabs and choanal cleft swabs are common sample types (Merck Veterinary Manual). The utility of molecular diagnostics in field settings is further described in the article Mycoplasma gallisepticum and Mycoplasma synoviae Infections in Chickens: Laboratory Diagnosis and Control Strategies.
Differential Diagnosis
Clinical signs of mycoplasmosis overlap with other avian respiratory and joint diseases. Differential diagnoses include avian colibacillosis, infectious coryza (caused by Avibacterium paragallinarum), fowl cholera (Pasteurella multocida), avian influenza, Newcastle disease, and infectious bronchitis. The article Infectious Coryza in Poultry and Ducks provides a detailed comparison. Synovitis caused by M. synoviae must be distinguished from bacterial arthritis due to Staphylococcus aureus or E. coli, and from reovirus tenosynovitis (Diseases of Poultry).
Vaccination Strategies
Vaccination is a cornerstone of control in multi‑age layer flocks and breeder operations where eradication is not feasible. Both live attenuated and inactivated (bacterin) vaccines are used.
Live Vaccines
Live vaccines for M. gallisepticum include the F‑strain, ts‑11, and 6/85 strains, each with different reactogenicity and protective efficacy. The F‑strain is moderately virulent but provides strong protection when administered via eyedrop or spray to pullets before lay. The ts‑11 strain (a temperature‑sensitive mutant) and 6/85 strain are more attenuated and can be used in situations where minimal shedding is desired. Live vaccines establish local immunity in the respiratory tract, reduce vertical transmission, and lessen clinical signs upon challenge. However, they can spread to unvaccinated flocks and may revert to virulence under field conditions (Merck Veterinary Manual; Diseases of Poultry). For M. synoviae, live vaccines (e.g., MS‑H strain) are available in some regions but are less widely used.
Inactivated Vaccines
Bacterin vaccines for M. gallisepticum are formulated with oil‑adjuvanted whole‑cell preparations and are administered by injection to breeders and layers. They induce strong humoral responses and reduce egg transmission but do not prevent colonization of the respiratory tract. Inactivated vaccines are often combined with live priming to optimize protection (Diseases of Poultry). The article Avian Mycoplasma Vaccine: Principles, Efficacy, and Application in Poultry discusses vaccine formulations and application protocols.
Vaccination Program Design
An integrated vaccination strategy typically includes live vaccine administration at 6–10 weeks of age, followed by an inactivated booster at 16–18 weeks for long‑lived layers and breeders. The goal is to reduce clinical disease, egg production losses, and vertical transmission. Because vaccination may interfere with serological surveillance, DIVA strategies using specific PCR assays that detect field strain markers are essential (Merck Veterinary Manual). The article Mycoplasma gallisepticum Vaccine in Poultry: Protocols and Efficacy provides further detail.
Antimicrobial Therapy and Resistance
Antimicrobial therapy can reduce clinical signs and shedding but does not eliminate the carrier state. Macrolides (tylosin, tilmicosin), tetracyclines (chlortetracycline, oxytetracycline), and pleuromutilins (tiamulin) are commonly used. However, resistance has been documented in many regions due to indiscriminate use. Antimicrobial susceptibility testing (broth microdilution) is recommended to guide therapy. Treatment is usually applied in feed or drinking water for 5–7 days. Because mycoplasmas lack a cell wall, β‑lactams are ineffective (Merck Veterinary Manual). The article Avian Enrofloxacin: Pharmacology, Clinical Use, and Resistance in Poultry discusses fluoroquinolone use, though enrofloxacin is not a first‑line mycoplasma drug.
Control and Eradication
Control programs are based on three strategies: eradication, vaccination, and medication. Eradication is achieved through serological testing and removal of infected flocks, combined with strict biosecurity. This is the gold standard for primary breeder companies. For commercial layers and broilers, a combination of vaccination, all‑in/all‑out management, and biosecurity is employed. Hatchery hygiene and treatment of hatching eggs with antibiotics or heat (e.g., egg dipping in tylosin solution) reduce vertical transmission (Diseases of Poultry). The World Organisation for Animal Health (WOAH) includes M. gallisepticum in its list of notifiable diseases for trade purposes. The article Mycoplasma in Poultry: Clinical Signs, Eye Infections, Treatment, and Control addresses clinical management in affected flocks.
graph TD
A[Flock with respiratory signs or lameness], > B[Collect samples: tracheal swabs, joint exudates, sera]
B, > C{Diagnostic approach}
C, > D[Serology: ELISA, SPA, HI]
C, > E[Molecular: qPCR for MG/MS]
C, > F[Culture (if required)]
D, > G{Result positive?}
E, > G
F, > G
G, >|Positive| H[Confirm species via PCR/sequencing]
H, > I[Determine strain characterization]
I, > J{Control strategy}
J, > K[Eradication: depopulation + cleaning]
J, > L[Vaccination program]
J, > M[Therapeutic medication]
K, > N[Biosecurity reinforcement]
L, > N
M, > N
N, > O[Flock monitoring by PCR/serology every 4–6 weeks]
Future Directions
Advances in molecular epidemiology using whole‑genome sequencing and multi‑locus sequence typing (MLST) enable high‑resolution tracking of strain transmission. Development of recombinant subunit vaccines and vector‑vaccines (e.g., fowlpox virus recombinants expressing M. gallisepticum adhesins) is underway. The integration of rapid point‑of‑care PCR devices on farms promises to accelerate diagnosis and targeted intervention.
References
- Diseases of Poultry. 13th edition. Swayne DE, editor. Wiley‑Blackwell; 2013.
- Merck Veterinary Manual. 11th edition. Aiello SE, Moses MA, editors. Merck & Co.; 2016.
- World Organisation for Animal Health (WOAH). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 3.3.5 – Avian Mycoplasmosis (M. gallisepticum).
For further reading on specific aspects, see the following cross‑linked articles on this portal:
Mycoplasma Infections in Poultry: Vaccination Strategies and Control Programs
Poultry Mycoplasma Infections: Vaccination Strategies and Control
Avian Mycoplasmosis: Vaccination Strategies and Control in Poultry Flocks
Avian Mycoplasma Vaccine: Principles, Efficacy, and Application in Poultry
Mycoplasma gallisepticum Vaccine in Poultry: Protocols and Efficacy
Mycoplasma in Poultry: Clinical Signs, Eye Infections, Treatment, and Control
Mycoplasma gallisepticum in Poultry: Chronic Respiratory Disease and Control Strategies
Mycoplasma iowae in Turkeys: Embryo Mortality, Hatchery Infections, and Diagnostic Control
Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.